Cargando…

Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study

INTRODUCTION: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Stessel, Björn, Vanvuchelen, Charlotte, Bruckers, Liesbeth, Geebelen, Laurien, Callebaut, Ina, Vandenbrande, Jeroen, Pellens, Ben, Van Tornout, Michiel, Ory, Jean-Paul, van Halem, Karlijn, Messiaen, Peter, Herbots, Lieven, Ramaekers, Dirk, Dubois, Jasperina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375318/
https://www.ncbi.nlm.nih.gov/pubmed/32788120
http://dx.doi.org/10.1016/j.thromres.2020.07.038
_version_ 1783561859108962304
author Stessel, Björn
Vanvuchelen, Charlotte
Bruckers, Liesbeth
Geebelen, Laurien
Callebaut, Ina
Vandenbrande, Jeroen
Pellens, Ben
Van Tornout, Michiel
Ory, Jean-Paul
van Halem, Karlijn
Messiaen, Peter
Herbots, Lieven
Ramaekers, Dirk
Dubois, Jasperina
author_facet Stessel, Björn
Vanvuchelen, Charlotte
Bruckers, Liesbeth
Geebelen, Laurien
Callebaut, Ina
Vandenbrande, Jeroen
Pellens, Ben
Van Tornout, Michiel
Ory, Jean-Paul
van Halem, Karlijn
Messiaen, Peter
Herbots, Lieven
Ramaekers, Dirk
Dubois, Jasperina
author_sort Stessel, Björn
collection PubMed
description INTRODUCTION: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. METHODS: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. RESULTS: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. CONCLUSION: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. REGISTRATION NUMBER: NCT04394000.
format Online
Article
Text
id pubmed-7375318
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73753182020-07-23 Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study Stessel, Björn Vanvuchelen, Charlotte Bruckers, Liesbeth Geebelen, Laurien Callebaut, Ina Vandenbrande, Jeroen Pellens, Ben Van Tornout, Michiel Ory, Jean-Paul van Halem, Karlijn Messiaen, Peter Herbots, Lieven Ramaekers, Dirk Dubois, Jasperina Thromb Res Full Length Article INTRODUCTION: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. METHODS: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. RESULTS: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. CONCLUSION: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. REGISTRATION NUMBER: NCT04394000. Elsevier Ltd. 2020-10 2020-07-22 /pmc/articles/PMC7375318/ /pubmed/32788120 http://dx.doi.org/10.1016/j.thromres.2020.07.038 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Stessel, Björn
Vanvuchelen, Charlotte
Bruckers, Liesbeth
Geebelen, Laurien
Callebaut, Ina
Vandenbrande, Jeroen
Pellens, Ben
Van Tornout, Michiel
Ory, Jean-Paul
van Halem, Karlijn
Messiaen, Peter
Herbots, Lieven
Ramaekers, Dirk
Dubois, Jasperina
Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
title Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
title_full Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
title_fullStr Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
title_full_unstemmed Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
title_short Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
title_sort impact of implementation of an individualised thromboprophylaxis protocol in critically ill icu patients with covid-19: a longitudinal controlled before-after study
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375318/
https://www.ncbi.nlm.nih.gov/pubmed/32788120
http://dx.doi.org/10.1016/j.thromres.2020.07.038
work_keys_str_mv AT stesselbjorn impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT vanvuchelencharlotte impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT bruckersliesbeth impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT geebelenlaurien impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT callebautina impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT vandenbrandejeroen impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT pellensben impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT vantornoutmichiel impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT oryjeanpaul impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT vanhalemkarlijn impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT messiaenpeter impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT herbotslieven impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT ramaekersdirk impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy
AT duboisjasperina impactofimplementationofanindividualisedthromboprophylaxisprotocolincriticallyillicupatientswithcovid19alongitudinalcontrolledbeforeafterstudy